BioSpace News Archive

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), announces that Mary Crowley Cancer Research center in Dallas, Texas is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitors, retifanlimab and epacadostat.

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation of previously approved drugs for neurological indications, today announced that it has entered into an exclusive licensing agreement with Myung In Pharm Co. Ltd (“Myung In Pharm”) to commercialize P2B001 for Parkinson’s disease (PD) in South Korea.

Strados Labs, a medical technology company harnessing the power of smart sensors to aid in early detection and predictions of worsening diseases for enhanced patient care, announced it was granted a CE Mark for the Company’s RESP™ Smart Sensor Platform for respiratory health.

The Lung Cancer Research Foundation and AstraZeneca have announced five research grant awards focused on understanding epidermal growth factor receptor inhibitor and immunotherapy resistance, totaling $900,000; giving each project $180,000 over a two-year period.

Filterlex Medical, a cardiovascular medical device startup, announced that it has recently completed a US $6 Million series A1 investment round from leading private healthcare investors.

GT Medical Technologies, Inc. a company dedicated to improving the lives of patients with brain tumors, today announced upcoming presentations related to its breakthrough GammaTile® Therapy at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO) being held in Boston November 18-21, 2021.

Investigators in a major clinical trial of patients with mild traumatic brain injury (mTBI, or concussion) describe for the first time objective diagnostic criteria, based on blood biomarkers and neurologic testing, for acute traumatic encephalopathy (ATE), the immediate physiologic consequence the injury.

Rockley Photonics, a global leader in photonics-based health monitoring and communications solutions, formed a strategic relationship to incorporate Rockley’s non-invasive biomarker sensing platform into potential clinical and healthcare research studies.

LifeSprout, Inc., a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, announced the appointment of Michael Kranda as CEO and member of the board of directors.

Today, Eli Lilly and Company (NYSE: LLY) announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the preventive treatment of episodic migraine in adults.